Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses

Jennifer G. Robinson; Michel Farnier; John J. P. Kastelein; Eli M. Roth; Marja-Riitta Taskinen; Helen M. Colhoun; Aurelie Brunet; A. Thomas DiCioccio; Guillaume Lecorps; Robert Pordy; Marie T. Baccara-Dinet; Christopher P. Cannon

doi:10.1016/j.jacl.2019.10.004

Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses

Jennifer G. Robinson, Michel Farnier, John J. P. Kastelein, Eli M. Roth, Marja-Riitta Taskinen, Helen M. Colhoun, Aurelie Brunet, A. Thomas DiCioccio, Guillaume Lecorps, Robert Pordy, Marie T. Baccara-Dinet, Christopher P. Cannon

Research output: Contribution to journal › Article › Scientific › peer-review

Original language	English
Journal	Journal of Clinical Lipidology
Volume	13
Issue number	6
Pages (from-to)	979-988
Number of pages	10
ISSN	1933-2874
DOIs	https://doi.org/10.1016/j.jacl.2019.10.004
Publication status	Published - Dec 2019
MoE publication type	A1 Journal article-refereed

Fields of Science

PCSK9
Low-density lipoprotein cholesterol
Monoclonal antibody
Cardiovascular
Clinical trial
Pharmacokinetic
CARDIOVASCULAR-RISK PATIENTS
HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
MONOCLONAL-ANTIBODY
INHIBITOR ALIROCUMAB
ADD-ON
EFFICACY
SAFETY
ATORVASTATIN
MONOTHERAPY
EZETIMIBE
317 Pharmacy

Access to Document

10.1016/j.jacl.2019.10.004

1-s2.0-S1933287419302880-mainFinal published version, 3.25 MBLicence: CC BY-NC-ND

Cite this

Robinson, J. G., Farnier, M., Kastelein, J. J. P., Roth, E. M., Taskinen, M-R., Colhoun, H. M., Brunet, A., DiCioccio, A. T., Lecorps, G., Pordy, R., Baccara-Dinet, M. T., & Cannon, C. P. (2019). Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses. Journal of Clinical Lipidology, 13(6), 979-988. https://doi.org/10.1016/j.jacl.2019.10.004

Robinson, Jennifer G. ; Farnier, Michel ; Kastelein, John J. P. ; Roth, Eli M. ; Taskinen, Marja-Riitta ; Colhoun, Helen M. ; Brunet, Aurelie ; DiCioccio, A. Thomas ; Lecorps, Guillaume ; Pordy, Robert ; Baccara-Dinet, Marie T. ; Cannon, Christopher P. / Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses. In: Journal of Clinical Lipidology. 2019 ; Vol. 13, No. 6. pp. 979-988.

@article{3d35c2bb81354987aa8ea5a27bada2ff,

title = "Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses",

keywords = "PCSK9, Low-density lipoprotein cholesterol, Monoclonal antibody, Cardiovascular, Clinical trial, Pharmacokinetic, CARDIOVASCULAR-RISK PATIENTS, HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, MONOCLONAL-ANTIBODY, INHIBITOR ALIROCUMAB, ADD-ON, EFFICACY, SAFETY, ATORVASTATIN, MONOTHERAPY, EZETIMIBE, 317 Pharmacy",

author = "Robinson, {Jennifer G.} and Michel Farnier and Kastelein, {John J. P.} and Roth, {Eli M.} and Marja-Riitta Taskinen and Colhoun, {Helen M.} and Aurelie Brunet and DiCioccio, {A. Thomas} and Guillaume Lecorps and Robert Pordy and Baccara-Dinet, {Marie T.} and Cannon, {Christopher P.}",

year = "2019",

month = dec,

doi = "10.1016/j.jacl.2019.10.004",

language = "English",

volume = "13",

pages = "979--988",

journal = "Journal of Clinical Lipidology",

issn = "1933-2874",

publisher = "EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC",

number = "6",

}

Robinson, JG, Farnier, M, Kastelein, JJP, Roth, EM, Taskinen, M-R, Colhoun, HM, Brunet, A, DiCioccio, AT, Lecorps, G, Pordy, R, Baccara-Dinet, MT & Cannon, CP 2019, 'Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses', Journal of Clinical Lipidology, vol. 13, no. 6, pp. 979-988. https://doi.org/10.1016/j.jacl.2019.10.004

Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses. / Robinson, Jennifer G.; Farnier, Michel; Kastelein, John J. P.; Roth, Eli M.; Taskinen, Marja-Riitta; Colhoun, Helen M.; Brunet, Aurelie; DiCioccio, A. Thomas; Lecorps, Guillaume; Pordy, Robert; Baccara-Dinet, Marie T.; Cannon, Christopher P.

In: Journal of Clinical Lipidology, Vol. 13, No. 6, 12.2019, p. 979-988.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses

AU - Robinson, Jennifer G.

AU - Farnier, Michel

AU - Kastelein, John J. P.

AU - Roth, Eli M.

AU - Taskinen, Marja-Riitta

AU - Colhoun, Helen M.

AU - Brunet, Aurelie

AU - DiCioccio, A. Thomas

AU - Lecorps, Guillaume

AU - Pordy, Robert

AU - Baccara-Dinet, Marie T.

AU - Cannon, Christopher P.

PY - 2019/12

Y1 - 2019/12

KW - PCSK9

KW - Low-density lipoprotein cholesterol

KW - Monoclonal antibody

KW - Cardiovascular

KW - Clinical trial

KW - Pharmacokinetic

KW - CARDIOVASCULAR-RISK PATIENTS

KW - HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

KW - MONOCLONAL-ANTIBODY

KW - INHIBITOR ALIROCUMAB

KW - ADD-ON

KW - EFFICACY

KW - SAFETY

KW - ATORVASTATIN

KW - MONOTHERAPY

KW - EZETIMIBE

KW - 317 Pharmacy

U2 - 10.1016/j.jacl.2019.10.004

DO - 10.1016/j.jacl.2019.10.004

M3 - Article

VL - 13

SP - 979

EP - 988

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

SN - 1933-2874

IS - 6

ER -